Primecap Management Co. CA Boosts Holdings in BioNTech SE (NASDAQ:BNTX)

Primecap Management Co. CA raised its stake in shares of BioNTech SE (NASDAQ:BNTX) by 2.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 4,763,453 shares of the company’s stock after buying an additional 131,490 shares during the period. Primecap Management Co. CA’s holdings in BioNTech were worth $502,735,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of BNTX. Cary Street Partners Investment Advisory LLC grew its position in BioNTech by 6.9% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company’s stock valued at $186,000 after buying an additional 111 shares during the period. Sectoral Asset Management Inc. raised its holdings in BioNTech by 3.5% in the 3rd quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company’s stock worth $374,000 after purchasing an additional 116 shares during the period. Dynamic Technology Lab Private Ltd boosted its position in BioNTech by 2.5% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock worth $492,000 after purchasing an additional 116 shares in the last quarter. CWM LLC grew its holdings in BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares during the period. Finally, Midwest Professional Planners LTD. increased its position in shares of BioNTech by 8.5% in the third quarter. Midwest Professional Planners LTD. now owns 2,822 shares of the company’s stock valued at $307,000 after buying an additional 220 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of BioNTech stock traded down $2.05 on Friday, hitting $96.95. 1,243,575 shares of the company were exchanged, compared to its average volume of 678,584. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $90.92 and a 200 day moving average price of $95.89. The stock has a market capitalization of $23.05 billion, a price-to-earnings ratio of 193.90 and a beta of 0.25. BioNTech SE has a 1-year low of $85.21 and a 1-year high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. As a group, sell-side analysts predict that BioNTech SE will post -1.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on BNTX shares. Evercore ISI initiated coverage on BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. BMO Capital Markets dropped their target price on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. TD Cowen upped their price target on shares of BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research report on Tuesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $113.00 price target on shares of BioNTech in a research note on Friday. Finally, UBS Group cut their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, BioNTech has an average rating of “Hold” and an average price target of $111.70.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.